Your browser doesn't support javascript.
loading
The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
Brian J Willett; Joe Grove; Oscar MacLean; Craig Wilkie; Nicola Logan; Giuditta De Lorenzo; Wilhelm Furnon; Sam Scott; Maria Manali; Agnieszka Szemiel; Shirin Ashraf; Elen Vink; William Harvey; Chris Davis; Richard Orton; Joseph Hughes; Poppy Holland; Sofia Vanessa Silva; David Pascall; Kathryn Puxty; Ana da Silva Filipe; Gonzalo Yebra; Sharif Shaaban; Matthew T.G. Holden; Rute Maria Pinto; Rory Gunson; Kate Templeton; Pablo Murcia; Arvind Patel; - The COVID-19 DeplOyed VaccinE (DOVE) Investigators; - COVID-19 EVADE Cohort Study; - The COVID-19 Genomics UK (COG-UK) Consortium; - The G2P-UK National Virology Consortium; John Haughney; David L Robertson; Massimo Palmarini; Surajit Ray; Emma C Thomson.
Afiliación
  • Brian J Willett; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Joe Grove; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Oscar MacLean; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Craig Wilkie; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Nicola Logan; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Giuditta De Lorenzo; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Wilhelm Furnon; MRC-University of Glasgow Centre for Virus Research, University of Glasgow,
  • Sam Scott; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Maria Manali; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Agnieszka Szemiel; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Shirin Ashraf; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Elen Vink; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • William Harvey; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Chris Davis; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Richard Orton; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Joseph Hughes; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Poppy Holland; NHS Greater Glasgow & Clyde, Queen Elizabeth University Hospital
  • Sofia Vanessa Silva; NHS Greater Glasgow & Clyde, Queen Elizabeth University Hospital
  • David Pascall; MRC Biostatistics Unit, University of Cambridge
  • Kathryn Puxty; Glasgow Royal Infirmary, NHS Greater Glasgow & Clyde, Glasgow, UK
  • Ana da Silva Filipe; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Gonzalo Yebra; Public Health Scotland
  • Sharif Shaaban; Public Health Scotland
  • Matthew T.G. Holden; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Rute Maria Pinto; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Rory Gunson; West of Scotland Specialist Virology Centre, NHS GG&C, Glasgow Royal Infirmary
  • Kate Templeton; Lothian Regional Virus Laboratory, Edinburgh
  • Pablo Murcia; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Arvind Patel; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • - The COVID-19 DeplOyed VaccinE (DOVE) Investigators;
  • - COVID-19 EVADE Cohort Study;
  • - The COVID-19 Genomics UK (COG-UK) Consortium;
  • - The G2P-UK National Virology Consortium;
  • John Haughney; NHS Greater Glasgow & Clyde, Queen Elizabeth University Hospital
  • David L Robertson; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Massimo Palmarini; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Surajit Ray; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
  • Emma C Thomson; MRC-University of Glasgow Centre for Virus Research, University of Glasgow
Preprint en Inglés | medRxiv | ID: ppmedrxiv-21268111
ABSTRACT
Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron, the fifth VOC to be described, harbours 30 amino acid mutations in spike including 15 in the receptor-binding domain. Here, we demonstrate substantial evasion of neutralisation by Omicron in vitro using sera from vaccinated individuals. Importantly, these data are mirrored by a substantial reduction in real-world vaccine effectiveness that is partially restored by booster vaccination. We also demonstrate that Omicron does not induce cell syncytia and favours a TMPRSS2-independent endosomal entry pathway. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.
Licencia
cc_by_nc_nd
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Idioma: Inglés Año: 2022 Tipo del documento: Preprint
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Idioma: Inglés Año: 2022 Tipo del documento: Preprint
...